StockData
Ensysce Biosciences, Inc. logo

Ensysce Biosciences, Inc. (ENSC) stock

ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$0.38−0.03 (-6.28%)

Close on Nov 17, 2026Market cap $7.47MP/E –Yield –

Ensysce Biosciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Ensysce Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$8.86M. For fiscal 2025 it was -$7.81M. The highest annual figure on record is -$1.24M in fiscal 2018.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$7.81M–
FY2024Dec 31, 2024-$7.50M–
FY2023Dec 31, 2023-$10.78M–
FY2022Dec 31, 2022-$17.89M–
FY2021Dec 31, 2021-$8.24M–
FY2020Dec 31, 2020-$1.25M–
FY2019Dec 31, 2019-$1.42M–
FY2018Dec 31, 2018-$1.24M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$1.96M–
Q1 FY2026Mar 31, 2026-$3.50M–
Q4 FY2025Dec 31, 2025-$1.53M–
Q3 FY2025Sep 30, 2025-$1.87M–
Q2 FY2025Jun 30, 2025-$2.71M–
Q1 FY2025Mar 31, 2025-$1.71M–
Q4 FY2024Dec 31, 2024-$764.09K–
Q3 FY2024Sep 30, 2024-$1.02M–
Q2 FY2024Jun 30, 2024-$2.31M–
Q1 FY2024Mar 31, 2024-$3.41M–
Q4 FY2023Dec 31, 2023-$1.80M–
Q3 FY2023Sep 30, 2023-$2.26M–
Q2 FY2023Jun 30, 2023-$3.11M–
Q1 FY2023Mar 31, 2023-$3.61M–
Q4 FY2022Dec 31, 2022-$3.30M–
Q3 FY2022Sep 30, 2022-$6.71M–
Q2 FY2022Jun 30, 2022-$4.44M–
Q1 FY2022Mar 31, 2022-$3.44M–
Q4 FY2021Dec 31, 2021-$3.77M–
Q3 FY2021Sep 30, 2021-$3.82M–
Q2 FY2021Jun 30, 2021-$132.31K–
Q1 FY2021Mar 31, 2021-$517.15K–
Q4 FY2020Dec 31, 2020-$533.86K–
Q3 FY2020Sep 30, 2020-$152.91K–
Q2 FY2020Jun 30, 2020-$326.19K–
Q1 FY2020Mar 31, 2020-$234.39K–
Q4 FY2019Dec 31, 2019-$425.76K–
Q3 FY2019Sep 30, 2019-$272.23K–
Q2 FY2019Jun 30, 2019-$432.44K–
Q1 FY2019Mar 31, 2019-$294.37K–
Q4 FY2018Dec 31, 2018-$458.64K–
Q3 FY2018Sep 30, 2018-$110.65K–
Q2 FY2018Jun 30, 2018-$452.14K–
Q1 FY2018Mar 31, 2018-$216.83K–

More Ensysce Biosciences figures

See a number that looks wrong?